Clinical Trial Update: Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients [Phase 1]

View source ↗

Summary

This Phase 1 pharmacokinetics and safety study evaluated ME1111 in patients with moderate-to-severe onychomycosis and has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• ME1111

Snippet

Sponsor: Meiji Seika Pharma Co., Ltd. | Conditions: Onychomycosis | Phase 1 | Status: COMPLETED